AstraZeneca’s Lynparza hits breast cancer trial targets
A late-stage study of AstraZeneca’s PARP inhibitor Lynparza in patients with HER2-negative metastatic breast cancer who also carry BRCA1 or BRCA2 mutations has its primary target of boosting progression-free survival (PFS).
Read More
